Immunologic parameters at baseline and 12 months after rituximab treatment
| . | Start . | End . | ||||
|---|---|---|---|---|---|---|
| . | Serum . | Supernatant . | Cryoprecipitate . | Serum . | Supernatant . | Cryoprecipitate . |
| Responders (n = 16) | ||||||
| IgM, mg/dL | 566.0 ± 281.4 | 263.0 ± 139.2 | 256.0 ± 220.2 | 336.5 ± 2303-150 | 324.6 ± 179.8 | 194.0 ± 238.8 |
| RF, IU/mL | 669.0 ± 1437.9 | 424.6 ± 346.1 | 642.4 ± 332.13-150 | 449.9 ± 1037.8 | 424.5 ± 346.5 | 514.7 ± 339.53-150 |
| IgG, mg/dL | 1553.2 ± 683.13-150 | 1155.6 ± 372.33-150 | 108.0 ± 124.2 | 1395.2 ± 665.9 | 1258.0 ± 508.2 | 67.6 ± 93.23-150 |
| C3, mg/dL | 124.3 ± 27.2 | 154.25 ± 41.5 | 1.8 ± 2.13-150 | 124.7 ± 34.9 | 141.8 ± 43.1 | 1.6 ± 3.3 |
| C4, mg/dL | 6.8 ± 4.2 | 5.6 ± 7.2 | 0.16 ± 0.113-150 | 8.8 ± 6.6 | 9.7 ± 7.6 | 0.1 ± 0.3 |
| Nonresponders (n = 4) | ||||||
| IgM, mg/dL | 414.2 ± 165.2 | 61.5 ± 173-150 | 410.5 ± 403.73-150 | 435.2 ± 389.4 | 53.0 ± 29.73-150 | 794.0 ± 2053-150 |
| RF, IU/mL | 489.7 ± 532.83-150 | 88.5 ± 17 | 600.5 ± 282.13-150 | 116.2 ± 74.43-150 | 81.5 ± 19 | 898.5 ± 680.9 |
| IgG, mg/dL | 1336.0 ± 504.1 | 715.5 ± 64.33-150 | 257.5 ± 266.6 | 1102.5 ± 439.7 | 888.0 ± 415.8 | 275.5 ± 328.8 |
| C3, mg/dL | 102.0 ± 25.0 | 118.5 ± 47.4 | 9.5 ± 0.73-150 | 98.5 ± 7.5 | 125.5 ± 41.7 | 2.5 ± 0.8 |
| C4, mg/dL | 4.0 ± 2.3 | 3.5 ± 2.1 | 0.5 ± 0.73-150 | 4.5 ± 1.7 | 3.5 ± 3.5 | 0.5 ± 0.4 |
| . | Start . | End . | ||||
|---|---|---|---|---|---|---|
| . | Serum . | Supernatant . | Cryoprecipitate . | Serum . | Supernatant . | Cryoprecipitate . |
| Responders (n = 16) | ||||||
| IgM, mg/dL | 566.0 ± 281.4 | 263.0 ± 139.2 | 256.0 ± 220.2 | 336.5 ± 2303-150 | 324.6 ± 179.8 | 194.0 ± 238.8 |
| RF, IU/mL | 669.0 ± 1437.9 | 424.6 ± 346.1 | 642.4 ± 332.13-150 | 449.9 ± 1037.8 | 424.5 ± 346.5 | 514.7 ± 339.53-150 |
| IgG, mg/dL | 1553.2 ± 683.13-150 | 1155.6 ± 372.33-150 | 108.0 ± 124.2 | 1395.2 ± 665.9 | 1258.0 ± 508.2 | 67.6 ± 93.23-150 |
| C3, mg/dL | 124.3 ± 27.2 | 154.25 ± 41.5 | 1.8 ± 2.13-150 | 124.7 ± 34.9 | 141.8 ± 43.1 | 1.6 ± 3.3 |
| C4, mg/dL | 6.8 ± 4.2 | 5.6 ± 7.2 | 0.16 ± 0.113-150 | 8.8 ± 6.6 | 9.7 ± 7.6 | 0.1 ± 0.3 |
| Nonresponders (n = 4) | ||||||
| IgM, mg/dL | 414.2 ± 165.2 | 61.5 ± 173-150 | 410.5 ± 403.73-150 | 435.2 ± 389.4 | 53.0 ± 29.73-150 | 794.0 ± 2053-150 |
| RF, IU/mL | 489.7 ± 532.83-150 | 88.5 ± 17 | 600.5 ± 282.13-150 | 116.2 ± 74.43-150 | 81.5 ± 19 | 898.5 ± 680.9 |
| IgG, mg/dL | 1336.0 ± 504.1 | 715.5 ± 64.33-150 | 257.5 ± 266.6 | 1102.5 ± 439.7 | 888.0 ± 415.8 | 275.5 ± 328.8 |
| C3, mg/dL | 102.0 ± 25.0 | 118.5 ± 47.4 | 9.5 ± 0.73-150 | 98.5 ± 7.5 | 125.5 ± 41.7 | 2.5 ± 0.8 |
| C4, mg/dL | 4.0 ± 2.3 | 3.5 ± 2.1 | 0.5 ± 0.73-150 | 4.5 ± 1.7 | 3.5 ± 3.5 | 0.5 ± 0.4 |
Statistically significant.